A coroner said Callum Cartlidge’s death would have been prevented if a blood test had been done.
Category Archives: Mind Building
A gut bacterium’s guide to building a microbiome
The mammalian gut is warm, moist, and incredibly nutrient-rich — an environment that is perfect for bacterial growth. The communities of “good bacteria” in the gut, commonly referred to as the microbiome, are vital partners for the body, helping to digest fiber, extract nutrients, and prevent various diseases. We are all familiar with the immune responses and illnesses that ensue from bad, or pathogenic, bacteria entering the body — so, if the immune system evolved to repel microbes, then how do mammals maintain harmonious relationships with the beneficial bacteria in the gut?
Now, new research from Caltech illustrates how a particular species of beneficial bacteria actually harnesses the body’s immune response so that it can settle down comfortably in the gut.
The work was done in the laboratory of Sarkis Mazmanian, Luis B. and Nelly Soux Professor of Microbiology and Heritage Medical Research Institute Investigator. A paper describing the research was published online on May 3 in the journal Science.
Led by graduate student Gregory Donaldson, researchers in the Mazmanian laboratory chose to examine a microbe called Bacterioides fragilis. The particular species is found abundantly in the large intestines of many mammals, including humans, and was previously shown by the Mazmanian lab to protect mice from certain inflammatory and neurological disorders such as inflammatory bowel disease and multiple sclerosis. Interestingly, though there are multiple strains of B. fragilis, healthy people form a long-term, monogamous relationship with only a single strain.
“Studies by other labs have shown that most people carry the same strain of B. fragilis throughout their lives,” says Donaldson. “We wanted to understand at a molecular level how these bacteria are able to colonize the gut in a stable, long-term way.”
First, the researchers aimed to examine B. fragilis‘s symbiotic relationship with the gut by physically looking at the locations where the bacteria reside. Using electron microscopy imaging on samples of mouse intestines, the team was able to see that B. fragilis clumps together in aggregates deep within the thick layer of mucus lining the gut, nestled close to the epithelial cells that line the surface of the intestine. Donaldson and his collaborators theorized that this spatial niche is necessary for a single species to settle in and establish a stable foothold.
The team next aimed to determine what mechanisms allow B. fragilis to colonize such a niche within the gut. They found that each B. fragilis bacterium is encased in a thick capsule made of carbohydrates. The capsule is typically associated with pathogens (bad bacteria) attempting to cloak themselves from recognition by and attack from the body’s immune system. Mutant bacteria lacking this capsule cannot aggregate and do not inhabit the mucosal layer. Thus, the researchers theorized that capsular carbohydrates are necessary for B. fragilis strains to monopolize their niche in the gut.
Because bacterial capsules were known to be related to an immune response in pathogenic bacteria, Donaldson and Mazmanian hypothesized that there may also be an immune response to the B. fragilis capsule. Indeed, they found that antibodies, immune proteins that grab onto and mark specific bacteria or viruses for other immune cells to engulf and destroy, were binding to the B. fragilis capsule in the intestine. One particular kind of antibody, immunoglobulin A or IgA, is found throughout the gut — in fact, it is the most abundantly produced type of antibody in humans — but its specific functions have been enigmatic.
Normally, an antibody response means imminent death to pathogenic bacteria. But curiously, IgA does not negatively affect most of the bacteria that normally live in the gut. In the case of B. fragilis, the researchers found, it actually helped the bacteria stick to epithelial cells. Furthermore, in mice that lacked IgA, the bacterium was less successful at colonizing the surface of the intestine and maintaining long-term stability.
The team believes that this IgA response to the B. fragilis capsule helps anchor the bacteria to the epithelial surface, thus providing an advantage.
“It is surprising to find that an immune response actually helps beneficial bacteria to thrive, which in turn helps the host thrive,” says Donaldson. “The study of immunology has mainly been in the context of pathogenic bacteria. But there are trillions of bacteria in the gut, and most of the time none of them are making you sick. Our study shows that there is active immune recognition of these bacteria, but it helps rather than hinders them. This suggests that the immune system is more than just a defense system and antibodies are more than just weapons.”
In future work, the researchers plan to study how the gut’s antibody response arises in the first place and why it helps B. fragilis while other antibodies hurt bacteria. Ultimately, this work could be used to improve colonization by other beneficial bacteria, as through the use of probiotics.
“Over the past decade, many studies have profiled the gut microbiome in a variety of diseases, lifestyles, geographies, and following birth,” says Mazmanian. “We’ve learned that the community composition of the microbiome correlates with particular conditions — for example, altered microbiome configurations may contribute to inflammatory bowel disease, autism, and Parkinson’s disease. What has remained largely unknown is how a microbiome is established and maintained in the first place. Our study reveals a molecular mechanism by which specific beneficial bacteria actively promote long-term intestinal colonization by engaging and co-opting the immune system, rather than trying to evade it as pathogens do. This discovery may lead to new ways to correct microbiome imbalances, and perhaps to prevent and treat a variety of human disorders.”

Health24.com | Get a body like boxer Anthony Joshua – here’s how
Anthony Joshua
Age: 27
Athlete type: Boxer
Height: 198cm
Weight: 113kg
Deadlifts + core
Power – the kind required to knock out 19 heavyweights in 19 fights since Joshua turned pro, a year after winning Olympic gold at London 2012 – does not come from heft alone.
In both physics and physiques, power is strength multiplied by speed. As Joshua executes a variety of explosive, punching movements and woodchoppers, his trainer, Jamie Reynolds constantly demands more speed.
Read more: Get ready to roll with the punches: Conor McGregor’s pro warmup
Joshua towers over the average Joe, and he’s adding muscle every year. It’s this massive frame that he’s leveraged to become a punishing force in the ring, combining mass and lightspeed velocity to throw knockout hits.
In his last fight, Joshua defended his IBF world heavyweight title against the veteran Ukrainian brawler Wladimir Klitschko. The pair battled relentlessly for 11 rounds, with both fighters falling to the mat and getting right back up to turn the tide with a torrent of punches.
However, it was Joshua who walked away victorious, his record unblemished, after a surge of energy did good on his promise to “unleash hell”, poleaxing Klitschko with two monster left hooks and knocking him out.
Read more: 3 boxing moves that can make you stronger and faster
During our interview, he adopts a boxing stance and pivots slowly at the waist. “Moving side to side, power goes through my glutes, my core. I think, ‘How can I transfer all the power, and make sure everything is balanced?’” he says. Joshua throws a fast four-punch combo.
Read more: Get ripped in a minute with this brutal boxing workout
He likes to accompany words with actions. “I’ve been doing a lot of bodyweight core work. Hanging on a bar…” He moves to the edge of his seat, lifts up his huge legs – 43cm calves and all – and points them out dead straight. His arms are straight out in front of him, as if he’s hanging on an imaginary bar. He stares down at his stomach. “Because your core is so important. It controls so much. So I hold my bodyweight in the air, with my legs in position.”
Critics – Tyson Fury the most vocal among them – have accused Joshua of spending too much time in the gym. “I don’t know what else I should be doing,” he responds. “Middleweights are ripped to shreds, but nobody calls them bodybuilders. There’s this idea that because I’m a heavyweight, I’m not supposed to be in condition, that I should take advantage of the fact that I can eat. But I train and eat well, and it shows when I step on the scales.
“The only weight I picked up was for deadlifts, which are for full-body strength and glutes. And that’s where the power comes from.”
Joshua’s genetics are a double-edged sword: His frame gives him reach, but those long levers make it harder to generate power. Even so, he throws a punch that – to steal a phrase from boxing writer Kevin Mitchell, following the Whyte fight – “would have decapitated a bull”. That’s testament to Joshua’s gym work, particularly on his core.
Read more: This two-week boxing programme is a killer total-body workout
Fighting history: Joshua’s vital stats beggar belief as much as his career (19 fights, wins and KOs). But the real insight comes through testimonials from his vanquished foes:
Fists: “He hits you through your gloves, even when you’ve got your hands up.” – Matt Legg, opponent no 6, who ended up with a broken eye socket
Legs: “A lot of guys his size don’t move as well… He’s 198cm, 113kg and he’s dancing around, throwing double-jabs.” – Jason Gavern, no 11
Eyes: “Joshua is very accurate. You can have a big, hard punch, but if it’s not timed correctly then it takes the sting out.” – Matt Skelton, no 7
This article was originally published on www.menshealth.com
Image credit: Supplied
NEXT ON HEALTH24X

Vaginal mesh op ‘should be last resort’ in Wales
But one woman who has had chronic pain since having mesh surgery wants them banned.
May the forest be with you: GEDI moves toward launch to space station
A first-of-its-kind laser instrument designed to map the world’s forests in 3-D is moving toward an earlier launch to the International Space Station than previously expected.
The Global Ecosystem Dynamics Investigation — or GEDI, pronounced like “Jedi,” of Star Wars fame — instrument is undergoing final integration and testing this spring and summer at NASA’s Goddard Space Flight Center in Greenbelt, Maryland. The instrument is expected to launch aboard SpaceX’s 16th commercial resupply services mission, targeted for late 2018. GEDI is being led by the University of Maryland, College Park; the instrument is being built at NASA Goddard.
“Scientists have been planning for decades to get comprehensive information about the structure of forests from space to deepen our understanding of how this structure impacts carbon resources and biodiversity across large regions and even globally, as well as a host of other science issues,” said Ralph Dubayah, GEDI principal investigator and a professor of geographical sciences at the University of Maryland. “This is why seeing the instrument built and racing toward launch is so exciting.”
From its perch on the exterior of the orbiting laboratory, GEDI will be the first space-borne laser instrument to measure the structure of Earth’s tropical and temperate forests in high resolution and three dimensions. These measurements will help fill in critical gaps in scientists’ understanding of how much carbon is stored in the world’s forests, the potential for ecosystems to absorb rising concentrations of carbon dioxide in Earth’s atmosphere, and the impact of forest changes on biodiversity.
GEDI will accomplish its science goals through an ingenious use of light. The instrument is a lidar, which stands for light detection and ranging. It captures information by sending out laser pulses and then precisely measuring the light that is reflected back.
GEDI’s three lasers will produce eight ground tracks — two of the lasers will generate two ground tracks each, and the third will generate four. As the space station and GEDI orbit Earth, laser pulses will reflect off clouds, trees and the planet’s surface. While the instrument will gather height information about everything in its path, it is specifically designed to measure forests. The amount and intensity of the light that bounces back to GEDI’s telescope will reveal details about the height and density of trees and vegetation, and even the structure of leaves and branches within a forest’s canopy.
NASA has flown multiple Earth-observing lidars in space, notably the ICESat (Ice, Cloud and land Elevation Satellite) and CALIPSO (Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observation) missions. But GEDI will be the first to provide high-resolution laser ranging of Earth’s forests.
“GEDI originally was scheduled to launch aboard a resupply mission in mid-2019, but the team at Goddard who is building and testing GEDI was always on track to deliver a finished instrument by the fall of this year,” said Project Manager Jim Pontius, making the move to an earlier resupply mission feasible. The team is now preparing to put GEDI through a battery of pre-launch tests to ensure it is ready to withstand the rigors of launch and operating in space.
NASA selected the proposal for GEDI in 2014 through the Earth Venture Instrument program, which is run by NASA’s Earth System Science Pathfinder (ESSP) office. ESSP oversees a portfolio of projects ranging from satellites, instruments on the space station, and suborbital field campaigns on Earth that are designed to be lower-cost and more focused in scope than larger, free-flying satellite missions.
Story Source:
Materials provided by NASA/Goddard Space Flight Center. Original written by Patrick Lynch. Note: Content may be edited for style and length.

Computing: Design for magnetoelectric device may improve memory
For years, manufacturers have offered computers with increasing amounts of memory packed into smaller devices. But semiconductor companies can’t reduce the size of memory components as quickly as they used to, and current designs are not energy-efficient. Conventional memory devices use transistors and rely on electric fields to store and read out information. An alternative approach being heavily investigated uses magnetic fields to store information. One promising version of magnetic device relies on the magnetoelectric effect which allows an electric field to switch the magnetic properties of the devices. Existing devices, however, tend to require large magnetic and electric fields that are difficult to produce and contain.
One potential solution for this problem is a new switching element made from chromia (Cr2O3), which, one day, may be used in computer memory and flash drives. “The device has better potential for scaling, so it could be made smaller, and would use less energy once it’s suitably refined,” said Randall Victora, a researcher at the University of Minnesota and an author on the paper. The researchers report their findings in Applied Physics Letters, from AIP Publishing.
Computer memory is composed of switching elements, tiny devices that can switch on and off to store bits of information as ones and zeros. Previous researchers discovered that chromia’s magnetoelectric properties means it can be “switched” with only an electric field, but switching requires the presence of a static magnetic field. Building on these elements, Victora and Rizvi Ahmed have created a design for a memory device with a heart of chromia that does not require any externally applied magnetic field to operate.
Their design surrounds the chromia with magnetic material. This provides an effective magnetic field through quantum mechanical coupling to Cr magnetic moments, while allowing devices to be arranged in a way that blocks stray magnetic fields from affecting nearby devices. An element to read out the state of the device, to determine if it’s in one or zero state, is placed on top of the device. This could potentially pack more memory into a smaller space because the interface between the chromia and the magnet is the key to the coupling that makes the device function. As the device shrinks, the greater surface area of the interface relative to its volume improves the operation. This property is an advantage over conventional semiconductors, where increases in surface area as size shrinks lead to greater charge leakage and heat loss.
Next, Victora and Ahmed aim to collaborate with colleagues who work with chromia to build and test the device. If successfully fabricated, then the new device could potentially replace dynamic random access memory in computers.
“DRAM is a huge market. It provides the fast memory inside the computer, but the problem is that it leaks a lot of charge, which makes it very energy-inefficient,” Victora said. DRAM is also volatile, so information disappears once the power source is interrupted, like when a computer crash erases an unsaved document. This device, as described in the paper, would be nonvolatile.
However, such a memory device will likely take years to perfect. One significant barrier is the device’s heat tolerance. Computers generate a lot of heat, and modeling predicts that the device would stop functioning around 30 degrees Celsius, the equivalent of a hot summer day. Optimizing the chromia, perhaps by doping it with other elements, may improve its functioning and make it more suitable to replace existing memory devices.
Story Source:
Materials provided by American Institute of Physics. Note: Content may be edited for style and length.

To treat pain, you need to treat the patient
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can’t always remedy. Pain can be amplified, by depression and anxiety, genetics and quality of life. Genetics can also play a role in how people experience pain.
Physicians are less prone to prescribe opioid medication to patients with long-term pain — but they need more treatment options.
Clinicians and researchers at UW Medicine’s Center for Pain Relief found that an in-depth questionnaire can help immensely. Their work to create a pain assessment adaptable to any primary care clinic was recently published in the Journal of General Internal Medicine.
“PainTracker,” as they call it, is an assessment that can be filled out online from any digital device or completed on paper.
“To effectively treat the patient, these questions should be asked,” said lead author Dale Langford, research assistant professor in anesthesiology and pain medicine at the University of Washington School of Medicine.
She and co-authors estimated that 40 to 60 percent of patients with chronic pain have inadequate pain management.
“This lack of progress may partly be due to the multidimensionality of chronic pain, which is not routinely incorporated into it assessment and management,” they wrote.
The assessment addresses the patient’s treatment history, goals and expectations, pain intensity, pain-related disability, problems with pain medication, and quality-of-life issues such as sleep, depression and anxiety. A body diagram helps to pinpoint where the pain is affecting most.
Before each follow-up appointment, patients complete a subset of questions that yields a visual graph showing areas of improvement. The graphs also help providers show how improvement in sleep, function, and mood often occurs before reduction in pain.
“PainTracker provides a richer picture of patients’ responses to chronic pain treatments than the 0-10 pain rating scale,” said co-author Mark Sullivan, UW professor of psychiatry.
David Tauben, UW chief of the pain medicine and a co-author of the paper, said the tool has “dramatically transformed” his ability to properly assess, treat, and manage chronic pain.
He described the case of a patient new to his clinic who had already seen seven other doctors, including two pain specialists and had been prescribed a high dose of opioids and sedatives. The patient’s comments in PainTracker indicated severe depression, moderate anxiety, poor quality of life, sleep apnea, and likely post-traumatic stress disorder. At their first meeting, Tauben said, the patient embraced the responsibility to improve his mood, sleep and other ways to improve his life quality.
The patient found relief with sleep-hygiene training, and resilience training from the center’s clinical psychologist. Under the center’s direction, he sought out functional rehabilitation sessions from a physical therapist. He took yoga at a studio and mindfulness classes led by one of the center’s physicians.
A sample of primary-care providers (N=30) found an early version of PainTracker easy to use (70 percent) and thought that it helped patients to participate in their pain management (77 percent).
PainTracker is not currently used outside of the UW Center for Pain Relief, but it incorporated more than 12 tests, which are freely available and described in the article. They include the Alcohol Use Disorders Identification Test (AUDIT), fibromyalgia symptoms (FS), Generalized Anxiety Disorder 7-item scale (GAD-7), Opioid Risk Tool (ORT), Snoring, tiredness, observation of stopped breathing (STOP), high blood pressure, and widespread pain index (WPI).

New approach for treating neuropathic pain
Neuropathic pain is the chronic, pathological pain that continues even when the cause of pain is removed. Causes include damage to nerve cells and medicines used to treat cancer. A collaboration between research groups from Indiana University in Bloomington, USA and Turku Centre for Biotechnology in Finland has discovered a novel therapeutic that appears to interrupt the signaling cascades in the body required for multiple forms of neuropathic pain.
Neuropathic pain is extremely common, affecting up to 5-10% of the population globally, and no cures or effective treatments are currently available. Moreover, chemotherapy-induced pain can be so extreme that it causes some patients with cancer to discontinue treatment and greatly impairs quality of life in survivors.
Prior to this study, researchers were aware that pathological pain is triggered by a biological pathway that is activated by binding of the excitatory transmitter glutamate to receptors called NMDARs. This process then triggers activation of an enzyme neuronal nitric oxide synthase (nNOS) that generates nitric oxide gas that plays a role in aberrant pain sensation. However, experimental drugs designed to block either the NMDAR receptor or the nNOS enzyme can cause intolerable side effects, such as memory impairment and motor dysfunction.
Now, researchers from Indiana University in Bloomington, USA and the Turku Centre for Biotechnology in Finland have demonstrated that an experimental molecule reduces neuropathic pain in rodents resulting from either nerve damage or a common chemotherapy drug.
The team in the University of Turku in Finland was able to design the molecule after discovering that a protein, NOS1AP, that is downstream of nNOS, triggers several biological pathways that are associated with abnormal glutamate signaling, including neuropathic pain.
The Indiana University group demonstrated that an experimental molecule designed by the Turku group to prevent nNOS signalling to NOS1AP reduced two forms of neuropathic pain in rodents. These forms of pain develop as result of either chemotherapeutic agent paclitaxel or nerve damage.
The treatment also disrupted markers of nociceptive signaling in the spinal cord when the test drug was injected at that site into mice. Importantly, the NOS1AP inhibitor did not cause typical motor side effects observed with previous experimental molecules that directly target NMDARs.
– Importantly, the chemical that prevents this signalling did not cause the negative side effects observed in previous experiments. Our studies suggest that the nNOS-NOS1AP interaction site is a previously unrecognized target for pain therapies,” says Professor Andrea Hohmann from the Indiana University in Bloomington.
The results suggest that the protein NOS1AP might be a valuable novel target in the development of more effective medicines to treat neuropathic pain.
“NOS1AP should be studied in more detail to find the best way to prevent this protein from contributing to chronic pain,” said Senior Researcher Michael Courtney from the University of Turku.
Story Source:
Materials provided by University of Turku. Note: Content may be edited for style and length.

Racing can be fatal to horses
Intense exercise can be fatal to racehorses, according to a new University of Guelph study.
Prof. Peter Physick-Sheard and a team of researchers examined 1,713 cases of racehorse deaths from 2003 to 2015, and found racing was connected to some of the deaths.
“The study reveals parallels between mortality and the intensity of the overall management of the horses, their lifestyle and the type of work they do,” said Physick-Sheard, Department of Population Medicine. “Training and racing at top speed within a short amount of time and space is a health risk for horses, as it would be for any other species, including humans.”
Most racing in North America involves intense exertion over a relatively short distance, he added.
Published recently in the Equine Veterinary Journal, the study is the first of its kind to compare mortality in three racing breeds, and represents the most complete data set on the issue so far.
With the support of Ontario’s racing regulatory body, the Alcohol and Gaming Commission, researchers analyzed race and trial run data from the Ontario horse racing industry. A provincial registry of racehorse mortality requires mandatory reporting of all deaths occurring within 60 days of a race or trial run.
“The industry is committed to using scientific research to mitigate health risks to animals, and this new research definitely holds insights that will help in that effort,” said Physick-Sheard.
His study aimed to characterize and quantify exercise-associated mortality in racehorses and identify breed differences.
Physick-Sheard said breed differences provide deeper insights into strategies that could reduce mortality, improve the welfare of racehorses and reduce the costs of participation in the sport.
He discovered that thoroughbreds had the highest exercise-associated mortality rate and risk. Out of every 1,000 races, 2.27 deaths were exercise-associated. About one per cent of racing thoroughbreds die annually in association with racing or trial runs.
The mortality rate and risk were lowest for standardbreds, at 0.28 deaths per 1,000 race starts, and an annual death rate of 0.23 to 0.24 per cent. This breed is given more extensive training preparation and racing, said Physick-Sheard.
Mortality related to high-intensity exercise in quarter horses was 1.49 deaths per 1,000 race starts, with an annual death rate of 0.60 to 0.69 per cent from the activity.
For all breeds, musculoskeletal injury was the major contributing cause of mortality.
Thoroughbreds and quarter horses also succumbed to dying suddenly and accidents.
“The industry has characteristics revealed by this data that point at mechanisms that could be used to significantly reduce mortality,” said Physick-Sheard. “You can use carefully targeted strategies to reduce risk and increase the safety of the sport, something to which the Ontario and the global racing industries are devoting a lot of time and energy.”
The study revealed that the sex of standardbreds strongly affects mortality risk, with young stallions at higher risk than mares or geldings. Among older horses, geldings have higher risk than males.
Thoroughbred stallions face higher risk than standardbred stallions.
Training strategies could be modified to address the animal welfare and economic implications, said Physick-Sheard.
“It is possible that the very behavioural attributes traditionally seen as conferring a competitive advantage may have an overall negative impact.”
The findings allow the industry to monitor and assess changes in management and racing practices, he said. Structural factors within the horseracing industry can be addressed through rule changes, knowledge and education, Physick-Sheard added. But the characteristics of the individual horse breeds also play a significant role in mortality risks and need to be considered.
“We’re starting to focus more on the things that are potentially inherent to the breeds of horse, as opposed to characteristics of the work they perform,” Physick-Sheard said. “As we get more insight into those horse factors, we become more aware of other influences that are possible causes of increased mortality risk.”

Failings in learning disability deaths, report finds
A review, commissioned after the death of Connor Sparrowhawk, found failings in one in eight deaths.

